NewAmsterdam Pharma to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
NewAmsterdam Pharma Company N.V. - Ordinary Shares (NAMS)
Company Research
Source: GlobeNewswire
NAARDEN, the Netherlands and MIAMI, Feb. 01, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that Michael Davidson, M.D., chief executive officer of NewAmsterdam Pharma and Ian Somaiya, chief financial officer, will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Wednesday, February 7, 2024 at 1:00 p.m. ET. A live webcast of the fireside chat will be available through the investor relations section of the NewAmsterdam Pharma website at ir.newamsterdampharma.com. Following the live webcast, an archived replay will be available on the Company’s website. About NewAmsterdam NewA
Show less
Read more
Impact Snapshot
Event Time:
NAMS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NAMS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NAMS alerts
High impacting NewAmsterdam Pharma Company N.V. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
NAMS
News
- NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024 [Yahoo! Finance]Yahoo! Finance
- NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024GlobeNewswire
- BioAge Appoints Renowned Cardiologist and Biopharma Entrepreneur Michael H. Davidson, MD, to its Board of DirectorsBusiness Wire
- NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular DiseaseGlobeNewswire
- NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer [Yahoo! Finance]Yahoo! Finance
NAMS
Sec Filings
- 4/29/24 - Form PRE
- 4/19/24 - Form 424B3
- 4/18/24 - Form EFFECT
- NAMS's page on the SEC website